Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GPCR
GPCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GPCR News
ACT Capital Management Fully Exits Structure Therapeutics Stake
1d ago
Fool
Analyst Reiterates Strong Buy Rating for VKTX Ahead of Earnings
Apr 28 2026
stocktwits
Viking Therapeutics Q1 Earnings Preview Highlights Losses and Market Potential
Apr 22 2026
stocktwits
Structure Therapeutics Appoints New COO
Apr 14 2026
seekingalpha
The 'Diabesity' Market Is Poised for Rapid Growth: Key Catalysts for Lilly and Novo Stocks.
Apr 07 2026
Barron's
SPDR S&P China ETF Analysts See 34.69% Upside
Apr 03 2026
NASDAQ.COM
Wegovy Pill Shows Superior Weight Loss Over Foundayo
Apr 02 2026
CNBC
Viking and Structure Intensify Competition in Obesity Drug Development
Mar 30 2026
stocktwits
B Group Initiates Position in Structure Therapeutics
Mar 22 2026
Fool
B Group Acquires Shares in Structure Therapeutics
Mar 22 2026
NASDAQ.COM
Novo Nordisk's High-Dose Wegovy Approved by FDA
Mar 19 2026
CNBC
Structure Therapeutics Reports Promising Phase 2 Data for Obesity Drug
Mar 16 2026
seekingalpha
Casdin Capital Reduces Stake in Structure Therapeutics
Feb 27 2026
Fool
Structure Therapeutics Reports Q4 Net Income of $33 Million
Feb 26 2026
seekingalpha
BVF Increases Stake in Structure Therapeutics with $11.2 Million Purchase
Feb 25 2026
Fool
Eli Lilly's Dominance in Obesity Drug Market Reinforced
Feb 23 2026
CNBC
Show More News
